Active Biotech AB (publ)

OM:ACTI Stock Report

Market Cap: SEK 137.5m

Active Biotech Future Growth

Future criteria checks 2/6

Active Biotech is forecast to grow earnings and revenue by 62.1% and 134.1% per annum respectively.

Key information

62.1%

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth44.6%
Revenue growth rate134.1%
Future return on equityn/a
Analyst coverage

Low

Last updated23 Oct 2024

Recent future growth updates

Recent updates

Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Jun 05
Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?

Feb 19
Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?

Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely

Jul 27
Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely

Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

May 07
Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Nov 09
Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

May 03
We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate

Jan 18
We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate

Earnings and Revenue Growth Forecasts

OM:ACTI - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202628-2N/A-21
12/31/20259-27N/A-271
12/31/2024N/A-39N/A-411
9/30/2024N/A-42-40-40N/A
6/30/2024N/A-44-42-42N/A
3/31/2024N/A-45-45-45N/A
12/31/2023N/A-46-46-46N/A
9/30/2023N/A-48-48-48N/A
6/30/2023N/A-51-50-50N/A
3/31/2023N/A-54-51-51N/A
12/31/2022N/A-58-55-55N/A
9/30/2022N/A-60-57-57N/A
6/30/2022N/A-57-55-55N/A
3/31/2022N/A-56-53-53N/A
12/31/2021N/A-50-46-46N/A
9/30/20216-38-35-35N/A
6/30/20216-35-33-33N/A
3/31/20216-32-29-29N/A
12/31/20207-32-32-32N/A
9/30/20201-39-38-38N/A
6/30/20202-40-37-37N/A
3/31/20203-36-40-40N/A
12/31/20198-34-36-36N/A
9/30/201912-32-35-35N/A
6/30/201916-31-37-37N/A
3/31/201921-35-38-38N/A
12/31/201820-37-41-41N/A
9/30/201821-88-41-41N/A
6/30/201821-88N/A-43N/A
3/31/201820-103N/A-44N/A
12/31/201720-109N/A-46N/A
9/30/201722-63N/A-52N/A
6/30/201721-67N/A-57N/A
3/31/201720-59N/A-61N/A
12/31/201619-60N/A-73N/A
9/30/201617-86N/A-86N/A
6/30/201618-97N/A-123N/A
3/31/201617-152N/A-187N/A
12/31/201516-194N/A-218N/A
9/30/201514-210N/A-245N/A
6/30/201512-243N/A-256N/A
3/31/201511-229N/A-243N/A
12/31/201410-232N/A-267N/A
9/30/201412-257N/A-157N/A
6/30/2014116-171N/A-159N/A
3/31/2014116-194N/A-170N/A
12/31/2013116-212N/A-102N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACTI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACTI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACTI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACTI's revenue (134.1% per year) is forecast to grow faster than the Swedish market (1.3% per year).

High Growth Revenue: ACTI's revenue (134.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ACTI's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 08:21
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Active Biotech AB (publ) is covered by 14 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Morten LarsenABG Sundal Collier
Stefan WaldenlindCarnegie Investment Bank AB
Thomas BowersDanske Bank